Efficacy and safety of Tripterygium wilfordii Hook F for CKD in Mainland China: A systematic review and meta‐analysis

Tripterygium wilfordii Hook F (TwHF) is a promising Chinese traditional medicine used to significantly reduce proteinuria and improve renal function. However, its efficacy and safety in treatment of chronic kidney disease need to be further explored in order to promote its application in clinics. Th...

Full description

Saved in:
Bibliographic Details
Published in:Phytotherapy research 2018-03, Vol.32 (3), p.436-451
Main Authors: Wang, Duo, Zhao, Xiao‐Han, Cui, Yi, Zhang, Tian‐Tian, Wang, Fang, Hu, Yong‐Hong
Format: Article
Language:English
Subjects:
Blood
chronic kidney disease
Confidence intervals
Creatinine
Disorders
Effectiveness
efficacy and safety
Health risk assessment
Immunosuppression
Kidneys
Medical treatment
Medicine
Meta-analysis
Nitrogen
Proteinuria
Regression analysis
Renal function
Safety
Sensitivity analysis
Side effects
Statistical analysis
systematic review
Therapy
Tripterygium wilfordii Hook F
Urea
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Tripterygium wilfordii Hook F (TwHF) is a promising Chinese traditional medicine used to significantly reduce proteinuria and improve renal function. However, its efficacy and safety in treatment of chronic kidney disease need to be further explored in order to promote its application in clinics. This review compared the efficacy and safety of TwHF with the placebo, conventional Western medicine and other immunosuppressive medicine in a range of kidney disorders. One hundred three randomized controlled trials were included. TwHF therapy decreased 24‐hr proteinuria by 0.59 g/day (95% confidence interval [CI; −0.68, −0.50]), serum creatinine level by 1.93 μmol/L (95% CI [−3.69, −0.17]), and blood urea nitrogen level by 0.24 mmol/L (95% CI [−0.41, −0.07]); increased the total effective rate by 27% (95% CI [1.24, 1.30]); and decreased the incidence of adverse reactions by 19% (95% CI [0.68, 0.96]) overall. Meta regression results showed that the duration of therapy and mean age of participants were the major sources of high heterogeneity. Sensitivity analysis demonstrated that our statistic results were relatively stable and credible. The present findings suggested that TwHF possibly has nephroprotective effects by decreasing proteinuria, serum creatinine level, and blood urea nitrogen level and no more adverse reactions compared with control group in most kidney disorders. However, these findings still need to be further confirmed by high‐quality trials.
ISSN:0951-418X
1099-1573
DOI:10.1002/ptr.5987